The estimated Net Worth of Goran Ando is at least $108 millier dollars as of 21 August 2024. Goran Ando owns over 5,000 units of EyePoint Pharmaceuticals Inc stock worth over $108,093 and over the last 6 years he sold EYPT stock worth over $0. In addition, he makes $0 as Independent Chairman of the Board at EyePoint Pharmaceuticals Inc.
Goran has made over 4 trades of the EyePoint Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of EYPT stock worth $39,750 on 21 August 2024.
The largest trade he's ever made was buying 5,000 units of EyePoint Pharmaceuticals Inc stock on 21 August 2024 worth over $39,750. On average, Goran trades about 877 units every 85 days since 2018. As of 21 August 2024 he still owns at least 13,150 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Goran Ando stock trades at the bottom of the page.
Dr. Goran A. Ando M.D. serves as Independent Chairman of the Board of the Company. Dr. Ando has had a distinguished career in the global pharmaceutical industry that has spanned nearly four decades. He began his career at Pfizer, Inc., where he held several senior clinical positions both in the U.S. and in Europe. Dr. Ando also served as President of the Astra Research Centre. He held various senior appointments at GlaxoSmithKline plc, including Research and Development Director for Glaxo Group Research. Dr. Ando then joined Pharmacia AB in 1995 as Executive Vice President and Deputy Chief Executive Officer to lead Research and Development with additional responsibilities for manufacturing, information technology, business development and M&A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food and Drug Administration (FDA) prior to Pharmacia's acquisition by Pfizer for $60 billion. More recently, Dr. Ando served as Chief Executive Officer of Cell Tech Group PLC as well as a member of the Board of Directors of Novo Nordisk A/S until March 2018. He has also served as Chairman of the Board for several European-based biopharmaceutical companies and he currently serves as a Board member of biopharmaceutical companies in Europe, U.S. and Singapore. He is a Senior Advisor at EW Healthcare Partners. Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.
Goran Ando is 71, he's been the Independent Chairman of the Board of EyePoint Pharmaceuticals Inc since 2018. There are no older and 18 younger executives at EyePoint Pharmaceuticals Inc.
Goran's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... et Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: